TCS ADD™ Connected Clinical Trials Wins the India Pharma Award 2022

Tata Consultancy Services’ Industry-Leading, Intelligent Decentralized Trials Platform Received the Recognition for Providing a Unified, Next-Gen Patient and Site-Centric Offering

PRESS RELEASE

MUMBAI, December 15, 2022: Tata Consultancy Services (TCS) (BSE: 532540, NSE: TCS) announced that the TCS ADD™ Connected Clinical Trials platform for decentralized trials, has won the India Pharma Award 2022 in the category, Excellence in Ancillary Pharma Services.

The India Pharma Awards recognize excellence and innovation in the pharma industry. TCS won alongside others in the pharma league including Pfizer, Abbott laboratories, and Sun Pharma and was chosen by the jury from among 25 ancillary services contenders.

TCS ADD Connected Clinical Trials was recognized for exemplifying innovation through its future-proof platform offerings that leverage smart devices and sensor-enabled technologies using AI, ML, and IoT. The platform connects patients, sites, and sponsors through a variety of offerings in kit and sample tracking, digital labels, medication adherence, eDiaries, eCOA/ePRO, eConsent, and Televisit, to carry out efficient and seamless clinical trials operations.

In addition, TCS ADD Connected Clinical Trials supports automated data collection, enables remote monitoring and oversight suitable for high frequency and a high volume of data. For pharma organizations worldwide, the platform has been instrumental in expediting speed to market and reducing end-to-end clinical R&D costs.

Earlier this year, the platform was named a leader in the 2022 IDC MarketScape for Life Science R&D Decentralized Clinical Trials Technology Solutions.

“We are pleased to receive this award for TCS ADD Connected Clinical Trials. This is a recognition of our investments in innovation using novel technologies across the entire clinical R&D value chain to deliver superior business outcomes for our clients. TCS ADD enables touchless and seamless patient experiences while adhering to global regulatory compliances. The platform’s cutting-edge, sensor-enabled smart technologies, modular nature, open architecture that facilitate forward and backward integrations, strong partner network, cloud-agnostic approach and strong services capabilities together make it the preferred decentralized trials platform in the industry,” said Rachna Malik, Global Head, TCS ADD Platforms.

“The pharma landscape has become increasingly complex and diverse. While India enjoys a supreme position in the global pharmaceutical market, the credit goes to innovators who have the potential to steer the industry to even greater heights,” said Yogesh Mudras, Managing Director, Informa Markets in India. “Keenly contested, coveted and closely observed by key stakeholders within the domain, the India Pharma Awards received more than 250 nominations this year. Our heartiest congratulations to TCS ADD™ Connected Clinical Trials on behalf of Informa Markets in India for the exemplary win.”

TCS ADD Connected Clinical Trials is part of the suite of platform offerings that include Metadata repository, Data Management, Analytics & Insights, Safety, and Regulatory.

About TCS ADD™ Platforms:

TCS ADD™ provides a suite of modern and open technology platform for life sciences that enables digital ecosystems, simplifies data complexity and provides faster access to new and effective drugs for patients in need. The platform is powered by our proprietary cognitive intelligence engine, data driven smart analytics and Internet of Things (IoT) that makes clinical trials more agile and safe. TCS ADD™ leverages the best of cloud architecture and personalized user experience design in compliance with quality guidelines and privacy regulations. To know more about the TCS ADD™ Life Sciences platforms, please visit https://www.tcs.com/tcs-add or write to us at add.platform@tcs.com

About Tata Consultancy Services (TCS)

Tata Consultancy Services is an IT services, consulting and business solutions organization that has been partnering with many of the world’s largest businesses in their transformation journeys for over 50 years. TCS offers a consulting-led, cognitive powered, integrated portfolio of business, technology and engineering services and solutions. This is delivered through its unique Location Independent Agile™ delivery model, recognized as a benchmark of excellence in software development.

A part of the Tata group, India's largest multinational business group, TCS has over 616,000 of the world’s best-trained consultants in 55 countries. The company generated consolidated revenues of US $25.7 billion in the fiscal year ended March 31, 2022, and is listed on the BSE (formerly Bombay Stock Exchange) and the NSE (National Stock Exchange) in India. TCS' proactive stance on climate change and award-winning work with communities across the world have earned it a place in leading sustainability indices such as the MSCI Global Sustainability Index and the FTSE4Good Emerging Index. For more information, visit www.tcs.com

TCS media contacts

Corporate
Communications & India

corporate.communications@tcs.com

saxena.kritika@tcs.com

+91 22 6778 9999

vanshika.sood@tcs.com

+91 22 67789098

Asia Pacific

y.tham@tcs.com

+65 9720 9005

Canada

tiffany.fisher@tcs.com

+1 416 456 7650

Latin America

alma.leal@tcs.com

+521 55 2095 6098

Australia and New Zealand

kelly.ryan@tcs.com

+61 422 989 682

Europe

joost.galema@tcs.com

+31 615 903387

Japan

douglas.foote@tcs.com

+81 80 2115 0989

Middle East & Africa

pragya.priyadarshini@tcs.com

+971 528656700

UK

t.doherty@tcs.com

+44(0)7759396160

USA

james.sciales@tcs.com

+1 917 981 7651

Contact

TCS is here to make a difference through technology.

We’re in it for good, driving positive change for the benefit of all.

Extraordinary expertise leads to remarkable results.

Want to be a global change-maker? Join our team.

Find the latest news about TCS in our Newsroom

Recent Press releases

Recent News

Recent recognitions

Upcoming events

TCS works hand in hand with world-leading investors.